Atopix Therapeutics
ClosedAbingdon, United Kingdom · Founded 2012
- Headquarters
- Abingdon
- Founded
- 2012
- Business Model
- B2B
- Last Round
- Venture RoundJun 2015
- Rounds
- 1
About
Atopix Therapeutics Limited was a privately held, clinical-stage biopharmaceutical company that developed oral CRTH2 antagonists for Th2-mediated diseases including atopic dermatitis and severe eosinophilic asthma. Its lead candidate OC459 was studied in Phase 2 trials for moderate-to-severe atopic dermatitis at European dermatology centres, and backup molecule ATX2417 was assessed in a Phase I study. Chiesi Farmaceutici acquired Atopix in 2016 to add the asthma portfolio.
Summary
Atopix Therapeutics is a Biotech company based in Abingdon, United Kingdom, founded in 2012. Its most recent funding was a Venture Round in Jun 2015. Investors include Silicon Valley Bank, SR One and Wellington Partners.
Funding History
Jun 2015
Investors
Similar Companies
One of the world's largest contract research organizations (CROs), providing end-to-end clinical ...
Global contract research organization providing comprehensive drug development and laboratory ser...
Specialty pharmaceutical company
Altos Labs combines academic science and industry development to create medicines that restore ce...
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/atopix-therapeutics"><img src="https://indexed.vc/api/badge/company/atopix-therapeutics" alt="Atopix Therapeutics on Indexed.vc" width="260" height="76" /></a>